BSBE Seminar丨Dr. Xiaoxu Li, School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL)
Despite major advances in our understanding and treatment of metabolic dysfunction–associated steatotic liver disease (MASLD), its global prevalence remains high, affecting approximately 30–38% of the population. Thus, there is an urgent need to develop new therapeutic strategies and further elucidate the mechanisms underlying MASLD development. In this seminar, I will first introduce a composite clinical trait, the metabolic health score, developed to predict the risk of MASLD and related metabolic disorders, offering a potential tool for early disease assessment and risk stratification. I will then describe how genetic and dietary factors shape the gut microbiota–liver bile acid axis and, in turn, influence hepatic metabolism, providing new insights into potential therapeutic targets for MASLD. Finally, I will present our preclinical and clinical studies of a liver X receptor (LXR) inverse agonist and discuss its therapeutic effects and mechanisms in MASLD. Together, these studies cover different aspects of MASLD, from risk prediction and underlying mechanisms to potential therapeutic approaches, with potential implications for its clinical use.